(Q37964595)

26 August 2017

Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma (English)

1 reference

26 August 2017

Mohammed Tanjimur Rahman

1

1 reference

26 August 2017

Kentaro Nakayama

2

1 reference

26 August 2017

Munmun Rahman

3

1 reference

26 August 2017

Naomi Nakayama

4

1 reference

26 August 2017

Masako Ishikawa

5

1 reference

26 August 2017

Atsuko Katagiri

6

1 reference

26 August 2017

Kouji Iida

7

1 reference

26 August 2017

Satoru Nakayama

8

1 reference

26 August 2017

Yoshiro Otsuki

9

1 reference

26 August 2017

Ie-Ming Shih

10

1 reference

26 August 2017

Kohji Miyazaki

11

1 reference

26 August 2017

language of work or name

English

0 references

publication date

2 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

118

1 reference

26 August 2017

11

1 reference

26 August 2017

2846-2857

1 reference

26 August 2017

Cancer statistics, 1995.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Ovarian clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

The candidate oncogene ZNF217 is frequently amplified in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Secondary cytoreduction for patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

CoREST is an integral component of the CoREST- human histone deacetylase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Coordinated histone modifications mediated by a CtBP co-repressor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Biological role and prognostic significance of NAC1 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Role of the proto-oncogene Pokemon in cellular transformation and ARF repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

A role for Kaiso-p120ctn complexes in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Comprehensive Genome Sequence Analysis of a Breast Cancer Amplicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

Ovarian atypical endometriosis: its close association with malignant epithelial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

7 January 2021

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

7 January 2021

Amplicon profiles in ovarian serous carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

7 January 2021

Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

7 January 2021

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

7 January 2021

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26598

7 January 2021

Identifiers

DOI

10.1002/CNCR.26598

1 reference

26 August 2017

1 reference